Merck – $1B Google AI Deal
Merck has entered a ~$1 billion enterprise agreement with Google Cloud to expand use of AI across its R&D and operational infrastructure, marking a major investment in AI-enabled drug development capabilities.
All categories
Regeneron – Gene Therapy Approved for Hearing Loss
Regeneron has received FDA approval for Otarmeni (lunsotogene parvec-cwha), the first gene therapy for genetic hearing loss caused by biallelic OTOF variants, marking a major milestone in sensory-organ gene therapy.
Beeline Therapeutics – $300M Launch
Beeline Therapeutics has emerged from stealth with approximately $300 million in financing, representing one of the largest recent biotech startup launches and signaling renewed investor appetite for platform-driven company creation.
Terremoto – $108M Series C Degrader Platform
Terremoto Biosciences has raised $108 million in a Series C financing to advance its covalent targeted protein degradation platform, including AKT1-targeting degraders into clinical development.
Neomorph – $100M Molecular Glue Financing
Neomorph has raised $100 million to advance its molecular glue platform, reinforcing investor confidence in next-generation targeted protein degradation technologies.What HappenedThe company secured $100M in financing to expand development of its molecular glue therapeutics…
Allogene – ALPHA3 Interim Analysis Incoming
Allogene Therapeutics announced it will present an interim futility analysis from its pivotal Phase 2 ALPHA3 trial of an allogeneic CAR-T therapy in first-line consolidation for large B-cell lymphoma (LBCL), with data expected on…
Cartherics – CAR-NK Manufacturing Expansion
Cartherics and Catalent have expanded their manufacturing partnership to support development and commercialization of iPSC-derived CAR-NK cell therapies. The agreement strengthens access to Catalent’s cGMP-compliant iPSC platform, supporting multiple programs including lead candidate CTH-401.What…
Life Biosciences – $80M Gene Therapy Financing
Life Biosciences has raised $80 million to support clinical development of its anti-aging gene therapy program, marking a notable financing event in the longevity and gene therapy space.What HappenedThe company secured $80M in financing…
Pfizer – SF R&D Site Closure
Pfizer announced the closure of its South San Francisco research site, citing underutilization and broader pressures in the biotech funding environment. The move reflects ongoing post-pandemic restructuring across large pharmaceutical companies and signals shifts…
Gilead – $5B Tubulis Acquisition
Gilead Sciences has agreed to acquire German biotech Tubulis in a deal worth up to $5 billion, significantly expanding its antibody-drug conjugate (ADC) platform capabilities. The transaction underscores the strategic importance of ADC technologies…
